Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 01 2023
Historique:
received: 31 03 2022
pubmed: 9 9 2022
medline: 4 1 2023
entrez: 8 9 2022
Statut: epublish

Résumé

Long non-coding RNA NEAT1 is the core structural component of the nuclear paraspeckle (PS) organelles and it has been found to be deregulated in multiple myeloma (MM) patients. Experimental evidence indicated that NEAT1 silencing negatively impacts proliferation and viability of MM cells, both in vitro and in vivo, suggesting a role in DNA damage repair (DDR). In order to elucidate the biological and molecular relevance of NEAT1 upregulation in MM disease we exploited the CRISPR/Cas9 synergistic activation mediator genome editing system to engineer the AMO-1 MM cell line and generate two clones that para-physiologically transactivate NEAT1 at different levels. NEAT1 overexpression is associated with oncogenic and prosurvival advantages in MM cells exposed to nutrient starvation or a hypoxic microenvironment, which are stressful conditions often associated with more aggressive disease phases. Furthermore, we highlighted the NEAT1 involvement in virtually all DDR processes through, at least, two different mechanisms. On one side NEAT1 positively regulates the posttranslational stabilization of essential PS proteins, which are involved in almost all DDR systems, thus increasing their availability within cells. On the other hand, NEAT1 plays a crucial role as a major regulator of a molecular axis that includes ATM and the catalytic subunit of DNA-PK kinase proteins, and their direct targets pRPA32 and pCHK2. Overall, we provided novel important insightsthe role of NEAT1 in supporting MM cells adaptation to stressful conditions by improving the maintenance of DNA integrity. Taken together, our results suggest that NEAT1, and probably PS organelles, could represent a potential therapeutic target for MM treatment.

Identifiants

pubmed: 36073514
doi: 10.3324/haematol.2022.281167
pmc: PMC9827177
doi:

Substances chimiques

MicroRNAs 0
RNA, Long Noncoding 0
NEAT1 long non-coding RNA, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-233

Références

Nature. 2015 Jan 29;517(7536):583-8
pubmed: 25494202
Clin Cancer Res. 2013 Jul 1;19(13):3337-44
pubmed: 23515406
Haematologica. 2019 Feb;104(2):e72-e76
pubmed: 30213829
Int J Biol Sci. 2021 Aug 3;17(13):3428-3440
pubmed: 34512157
J Biol Chem. 2003 May 2;278(18):15911-6
pubmed: 12606543
Cell. 2013 Feb 28;152(5):1173-83
pubmed: 23452860
Leukemia. 2018 Dec;32(12):2604-2616
pubmed: 29789651
Leukemia. 2018 Sep;32(9):1948-1957
pubmed: 29487387
Am J Transl Res. 2020 Jul 15;12(7):3871-3883
pubmed: 32774741
Noncoding RNA. 2020 Jul 01;6(3):
pubmed: 32630183
EMBO J. 2012 Oct 17;31(20):4020-34
pubmed: 22960638
Leukemia. 2020 Jan;34(1):234-244
pubmed: 31427718
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Nat Methods. 2013 Oct;10(10):977-9
pubmed: 23892898
Trends Biochem Sci. 2018 Feb;43(2):124-135
pubmed: 29289458
Bioessays. 2021 May;43(5):e2000245
pubmed: 33748979
Cell Physiol Biochem. 2019;52(3):368-381
pubmed: 30845377
Ther Adv Med Oncol. 2020 Sep 14;12:1758835920956900
pubmed: 32973933
Nat Cell Biol. 2011 Jan;13(1):95-101
pubmed: 21170033
Nat Med. 2016 Aug;22(8):861-8
pubmed: 27376578
Leukemia. 2015 Oct;29(10):2015-23
pubmed: 25971364
Semin Cell Dev Biol. 2019 Feb;86:112-120
pubmed: 29665433
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Cell Cycle. 2017 Jan 17;16(2):137-138
pubmed: 27700225
Genome Res. 1997 Jul;7(7):725-35
pubmed: 9253601
Cell Prolif. 2017 Apr;50(2):
pubmed: 28105699
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019064

Auteurs

Elisa Taiana (E)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan. elisa.taiana@unimi.it.

Cecilia Bandini (C)

Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy; Città Della Salute e della Scienza Hospital, 10126 Turin.

Vanessa Katia Favasuli (VK)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan.

Domenica Ronchetti (D)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan.

Ilaria Silvestris (I)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan.

Noemi Puccio (N)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan.

Katia Todoerti (K)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan.

Silvia Erratico (S)

Novystem Spa, Milan, Italy; Stem Cell Laboratory, Department of Pathophysiology and Transplantation, University of Milan, Centro Dino Ferrari, Unit of Neurology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan.

Domenica Giannandrea (D)

Department of Health Sciences, University of Milan, 20142 Milan.

Niccolò Bolli (N)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan.

Nicola Amodio (N)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro.

Alessia Ciarrocchi (A)

Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, 42123 Reggio Emilia.

Raffaella Chiaramonte (R)

Department of Health Sciences, University of Milan, 20142 Milan.

Yvan Torrente (Y)

Stem Cell Laboratory, Department of Pathophysiology and Transplantation, University of Milan, Centro Dino Ferrari, Unit of Neurology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan.

Roberto Piva (R)

Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy; Città Della Salute e della Scienza Hospital, 10126 Turin.

Antonino Neri (A)

Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy 20122 Milan. antonino.neri@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH